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Abstract
Background: Insulin-like growth factors (IGFs) are important for the proliferation of cancer cells.
One of their binding proteins, known as insulin-like growth factor binding protein -4 (IGFBP-4) is
well known for its inhibitory action on IGFs in vitro. We assessed the effect of IGFBP-4 in prevention
of development of colon cancer in vivo.
Methods: Nude mice were subcutaneously inoculated with HT-29 colon cancer cells and they
were also simultaneously injected either gene construct containing mammalian expression vector
pcDNA3 with or without IGFBP-4 gene or phosphate buffered saline. The effect was assessed 4
weeks later by evaluating the tumours for mitosis, necrosis, apoptosis, and expressions of IGFBP-
4, Bcl-2 and Bax proteins.
Results: The results showed that the IGFBP-4 gene therapy did not prevent the tumour
establishment but it increased the tumour apoptosis which was associated with an increase in Bcl-
2 and Bax expressions. The IGFBP-4 protein was low in tumours which received IGFBP-4 gene
construct which may be due to a feed back mechanism of IGFBP-4 upon its own cells.
Conclusion: IGFBP-4 gene therapy in the form localised gene transfer did not prevent colon
cancer initiation and establishment but it resulted in increased apoptosis and Bax protein
expression and a decrease in tumour cellular mitosis
Background
Colon cancer is the second leading cause of morbidity and
mortality in the developed countries [1]. Several treat-
ment options are available for established colon cancer
depending upon the stage of the disease. No proven treat-
ment option is available to date in preventing the estab-
lishment and development of colon cancer other than
prophylactic total colectomy. Colon cancer development
is influenced by several growth factors. Among these
growth factors, insulin-like growth factor (IGF) system has
been shown to play an important role in cancer develop-
ment [2]. The IGF system consists of two growth factors
(IGF-I and IGF-II), their binding proteins, receptors and
proteases. One of the IGF binding proteins called IGFBP-
4 is well known for its growth inhibitory effect on several
cancer cells in vitro [3,4]. In our previous studies, we found
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ous cancer model can increase tumour apoptosis and
decrease tumour cellular mitosis [5]. To explore the role of
the IGFBP-4 in prevention of colon cancer establishment,
we simultaneously administered gene construct contain-
ing IGFBP-4 cDNA at the same time when the subcutane-
ous cancer was induced in nude mice. The effect of IGFBP-
4 on cancer initiation and development was then assessed
by examining tumour volume, tumour histology, tumour
cellular apoptosis and some proteins expression. In this
paper we are presenting the results of our in vivo experi-
ment.
Methods
Gene construct
Mammalian expression vector pcDNA 3 (Invitrogen,
Carlsbad, CA, USA) containing IGFBP-4 gene, which was
inserted between Kpn I and EcoR I restriction enzyme sites
downstream of cytomegalovirus promoter, and light
chain myosin enhancer was used. Plasmid DNA prepara-
tion and purification was performed using the Endo Free
Plasmid Maxi Kit (Qiagen, Crawley, UK) and IGFBP-4
insert and its reading frame were confirmed by sequenc-
ing (MWG, Ebersberg, Germany) prior to animal experi-
ment.
Colon cancer cell culture
HT-29 human colon adenocarcinoma cells (European
Collection of Cell Cultures, Porton Down, Dorset, UK)
were cultured in 75 cm3 flasks with McCoy's 5A Medium
(GIBCO, Paisley, UK) containing glutamine (2 mM), 10%
foetal bovine serum and 1% Penicillin (5000 unit/ml)
and streptomycin (5000 μg/ml) at 37°C in an atmosphere
of 5% CO2. 10 flasks of such cells were used. After 48
hours, the medium was extracted, the cells were washed
twice with 10 mls of phosphate buffered saline (PBS) and
then cultured in 20 mls of fresh medium under standard
conditions until they reach to 90% confluent. Cells were
then washed with 10 mls of PBS twice before they were
trypsinised, neutralised with bovine serum and centri-
fuged at 900 G for 5 minutes. A final concentration of 12
mls of cells (5 × 106/ml of >90% viability as determined
by Tryphan Blue) was obtained and 0.6 mls (3 × 106/ml
cells in PBS) was injected subcutaneously into the flank of
each nude mouse.
Animal model
The experiment was conducted under a project licence,
granted by the Home Office, UK, in accordance with the
Animals (Scientific Procedures) Act 1986. 4–6 weeks old
MF1 nu/nu male athymic mice were bought from Com-
parative Biology Unit, Royal Free and University College
School, London, UK. The animals were randomly divided
into three groups of 6 each. Group 1 received HT-29 cells
alone in PBS (Control P), group 2 received a mixture of
control plasmid and HT-29 cells (Control M) and group 3
received a mixture of HT-29 and gene construct contain-
ing IGFBP-4 cDNA (BP-4 group). Plasmids were used at
150 μg/animal in PBS and quantified prior to the animal
experiment in UV spectrophotometer. The procedure was
carried out under light enfluorane general anaesthesia and
the cells/plasmid mixtures were injected into the flank
subcutaneously with insulin syringes. The animals were
kept in 4 per cage, each cage was separately marked and
the animals in each cage were identified by ear punch. The
experiment was terminated in 4 weeks after tumour
induction. The tumour size was measured at two time
points using a digital vernier caliper.
Tumour volume
Four weeks after inoculation with cancer cells, the animals
were sacrificed by schedule 1 method and tumours were
harvested. Tumour volume was measured and calculated
by a method described previously i.e. (the shortest diam-
eter)2 × (the longest diameter) × 0.5 [6]. The tumour tis-
sues were divided into four portions and stored in
appropriate medium for future assessment.
Tumour histology
Paraffin sections were made from tumour samples which
were fixed in 10% formalin. Haematoxylin and eosin
(H&E) staining was carried out and the tumour sections
were assessed for cell death and scored. Necrosis found in
<1%, 1–20%, 21–40%, 41–60%, 61–80% and 81–100%
of the region of interest were scored as 0, 1, 2, 3, 4 and 5
respectively [6,7]. Tumour proliferative activity was meas-
ured by counting the mitotic figures blindly in H&E
stained tumour sections on 10 random high power fields
(× 400) [8]. Mitotic figures in anaphase through early tel-
ophase were included in the counting.
Assessment for apoptosis
Tumour apoptosis was investigated by both Terminal
deoxynucleotidyl transferase biotin-dUTP nick end label-
ling (TUNEL) assay and electron microscopy.
TUNEL assay
TUNEL assay was carried out with Apotag-red kit (Serolog-
icals Corporation, Temecula, CA, USA) to assess apopto-
sis. Tumour sections were fixed in 5% formalin for 10
minutes at room temperature and washed in PBS twice for
5 minutes per each wash. The manufacturer's protocol
was then followed for the remaining step.
Electron microscopy
Transmission electron microscopy was performed to
assess the ultra structure of the cancer cells to confirm and
correlate the apoptosis with those of the TUNEL assay
findings. Ultra thin sections (60–90 nm) were cut with a
diamond knife and stained with uranyl acetate and leadPage 2 of 8
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and ultra structures of cancer cell were photographed
using a Philips CM120 transmission electron microscope.
Assessment of IGFBP-4 by Western immunoblot
The frozen tumour tissues were powdered in liquid nitro-
gen and the cells were lysed in reporter lysis buffer
(Promega, USA). Total proteins were quantified by modi-
fied Lowry protein assay (Pierce Biotechnology, Rockford,
IL, USA). 50 μg of total protein from each tumour sample
in 10 μl of PBS were mixed with an equal volume of lae-
mmi (2× Sigma-Aldrich, Gillingham, UK) sample buffer.
The samples were then denatured by heating in a water
bath at 95°C for 5 minutes. Sodium dodecyl sulphate –
polyacrylamide gel electrophoresis was used to separate
the proteins, which was then electro blotted on to polyvi-
nylidene fluoride (PVDF) membrane (Bio-Rad Lab, Her-
cules, CA, USA). The membrane was then blocked with
5% milk (Marvel semi skimmed milk powder, UK) for 30
minutes. The membrane was incubated with rabbit anti-
IGFBP-4 polyclonal antibody (Santa-Cruz Biotechnology,
Santa Cruz, CA, USA) at 1/200 dilution followed by incu-
bation with Horse radish peroxidase (HRP) secondary
antibody conjugate (Dako, Ely, UK) at 1/2000 dilution.
The membrane was illuminated with Super Signal West
Dura Extended Duration Substrate (Pierce, USA) and
exposed to X-ray film for 10 seconds (Fuji, Japan). The X-
ray was scanned and the density of the protein bands were
analysed with Bio-rad densitometry software (Molecular
Analyst, Windows software for Bio-rad's image analysis
system version 1.5, USA).
Assessment of Bax and Bcl-2 expressions by Western blot
The procedure for Western blot is the same as for the
IGFBP-4. Rabbit anti-mouse Bcl-2 polyclonal antibody
(Santa-Cruz Biotechnology, Santa Cruz, CA, USA) or rab-
bit anti-mouse Bax polyclonal antibody (Santa-Cruz Bio-
technology, USA) both at 1/200 dilution were used,
followed by incubation with secondary antibody conju-
gate with horse radish peroxidase (HRP) (Dako, Ely, UK)
at 1/2000 dilution.
Statistics
One way ANOVA with Dunnett post hoc test (Graph pad,
Prism version 4 2004 edition, USA) was used for statistical
calculations and P <0.05 was considered as significant.
Results
Tumour establishment, volume and weight
All animals developed subcutaneous tumours. There was
no local or distant spread of cancer. Both tumour weight
and volume showed a reduction in animals which
received plasmid treatment although there was no statisti-
cal difference in the final tumour weight (grams) (1.70 ±
0.17 vs 0.98 ± 0.16 vs 1.19 ± 0.25; Control P vs Control M
vs BP-4; P = 0.06) (figure 1a) or tumour volume (mm3)
(2060.25 ± 379.62 vs 829.99 ± 194.81 vs 1007.71 ±
246.67; Control P vs Control M vs BP-4; P = 0.69) (figure
1b) between Control and BP-4 group.
Tumour histology
There was an attempted glandular formation with areas of
cell death. The mean area of cell death was significantly
higher in BP-4 group tumours than the other two control
group tumours (2.20 ± 0.22 vs 1.76 ± 0.23 vs 0.66 ± 0.14,
BP-4 vs Control M vs Control P, P = 0.0007). Figures 2a, b
and 2c show the representative photomicrographs of
tumours after H&E staining in each group and figure 2d
shows the cell death score. The average numbers of
mitotic figures per field were lower in BP-4 group tumours
than the control group tumours (2.03 ± 0.53 vs 3.13 ±
0.99 vs 7.00 ± 1.72, BP-4 vs Control M vs Control P, P =
0.03) (figure 2e).
Tumour apoptosis
TUNEL assay demonstrated higher numbers of apoptotic
cells in tumours of the BP-4 group than the control groups
(figure 3). Apoptotic index is plotted in figure 3d. It
showed that IGFBP-4 gene therapy treatment resulted in
Showing final weight (a) and tumour volumes on week 1 and 4 after tumour induction (b) of tumours of BP-4 tr ated, con rol M and control P groupsFigure 1
Showing final weight (a) and tumour volumes on week 1 and 
4 after tumour induction (b) of tumours of BP-4 treated, 
control M and control P groups. There was no statistical dif-
ference between control M and BP-4 treated tumours. Val-
ues are expressed as mean ± SEM.Page 3 of 8
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compared to control group tumours (apoptotic cells/100
total cells) (11.47 ± 1.51 vs 3.59 ± 0.17 vs 4.47 ± 0.55, BP-
4 vs Control M vs Control P, P = 0.0002). Transmission
electron microscopy (figure 4a–e) also demonstrated
higher numbers of cells undergoing apoptosis in tumours
of BP-4 group while less numbers of such cells were noted
in tumours of control groups.
IGFBP-4 protein expression
Western blot and densitometry analysis (figure 5) showed
a decreased expression of IGFBP-4 by tumours of both BP-
4 and control M groups and an increased expression by
Control P group (0.63 ± 0.03 vs 0.75 ± 0.09 vs1.04 ± 0.06,
BP-4 vs control M vs Control P, P = 0.002).
Expression of Bax and Bcl-2 Proteins
The Bax protein was over-expressed in tumours after
IGFBP-4 gene therapy when compared with control
groups (3.37 ± 1.15 vs 4.11 ± 1.30 vs 6.31 ± 1.16; Control
P vs Control M vs BP-4; P = 0.23) (figure 6). The mean Bcl-
2 expression was higher (2.27 ± 0.65 vs 1.01 ± 0.25 vs 6.06
± 1.77, Control P vs Control M vs BP-4, P < 0.01) in BP-4
treated tumours when compared with the control group
(figure 7).
Discussion
In this study we assessed the preventive role of IGFBP-4 in
colon cancer in the form of gene therapy in vivo and found
that IGFBP-4 did not prevent the establishment of cancer
in HT-29 colon cancer model but it increased the cell
Photomicrographs (×200) showing H&E staining of tumours of (a) BP-4 (b) control M (c) control P groupsFigure 2
Photomicrographs (×200) showing H&E staining of tumours of (a) BP-4 (b) control M (c) control P groups. Increased areas of 
necrosis (arrow) and decreased cellular density are present in BP-4 treated tumours when compared to control groups. (d) 
Showing cell death score of tumours. The animals received a single administration of either saline or gene construct with and 
without BP-4 along with colorectal cancer cells. Results are shown as mean ± SEM of 6 animals in each group. (e) Showing 
average numbers of mitotic figures per section per field of tumours. Values are expressed as mean ± SEM of 6 animals in each 
group. (key: P – animals without plasmid therapy, M – animals which received control plasmid, BP-4 – animals which received IGFBP-4 
gene.)Page 4 of 8
(page number not for citation purposes)
World Journal of Surgical Oncology 2007, 5:128 http://www.wjso.com/content/5/1/128death, apoptosis and decreased tumour proliferation. This
increase in apoptosis was associated with an increase in
Bax protein expression.
Apoptosis is a mechanism of single cells death in which
mitochondria play an important role. During apoptosis,
cells shrink in their size and there is condensation of chro-
matin resulting in the formation of apoptotic bodies [9].
It is characterised by extensive DNA fragmentation [10]
with no accompanying inflammation. In contrast to this,
necrosis results in cellular swelling and there is inflamma-
tory response.
In our experiment, histopathological examination of
tumour tissue showed increased areas of cell death and
fewer mitotic figures in BP-4 group tumours when com-
pared to control group tumours. TUNEL assay and elec-
tron microscopy both confirmed these dead cells as
apoptotic cells. Apoptotic index was significantly higher
in tumours of BP-4 group when compared with controls.
Apoptosis is influenced by various intracellular proteins
and enzymes. IGFs, cause cellular proliferation and by
their anti apoptotic action [11], prolong cell survival. IGFs
act on IGF-IR which in turn alters various intra cellular
proteins and enzymes. Apoptosis is influenced by the
actions of various intracellular pro-apoptotic and anti-
apoptotic proteins. The pro-apoptotic proteins belong to
Bax subfamily and anti-apoptotic proteins belong to Bcl-
2 subfamily. IGF-I acts at different control points of apop-
tosis, including the Bcl-2 family proteins, inhibitors of
caspases and signalling of death-inducing receptors [12].
Bax protein plays an important role in cellular apoptosis
[13]. It can form a transmembrane pore across the outer
mitochondrial membrane, leading to loss of membrane
potential and efflux of cytochrome c and apoptosis induc-
ing factor. IGF-I not only down regulate the Bax expres-
sion [14] but also prevent its translocation to
mitochondria [15], inhibits the activation of caspase 3
[16,17] and release of cytochrome c from the mitochon-
dria [16]. Bcl-2 inhibits the release of cytochrome c from
the mitochondria and thereby it may influence apoptosis.
Representative photomicrographs showing TUNEL assay of tumours (× 200) from (a) BP-4 group (b) control M and (c) control P groupsFi ure 3
Representative photomicrographs showing TUNEL assay of tumours (× 200) from (a) BP-4 group (b) control M and (c) control 
P groups. Apoptotic cells were detected by red immunofluorescence. BP-4 treated tumours show increased numbers of apop-
totic cells (arrow) compared with the other two groups (d) Comparison of apoptotic indices among the tumours of BP-4, con-
trol M and control P groups. BP-4 group tumours had higher apoptotic index than control groups. Values are shown as mean ± 
SEM of 6 animals in each group.Page 5 of 8
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IGFBP-4 gene therapy on a previously established subcu-
taneous cancer model and found that the IGFBP-4 and
IGF-1R were overexpressed by the tumours. There was an
associated increase in Bax and a decrease in Bcl-2 proteins
after the gene therapy. TUNEL assay demonstrated an
increase in apoptotic index by the tumours after IGFBP-4
gene therapy. However, the tumours did not regress after
gene therapy.
In our current study, tumour volume and weight were
similar in both BP-4 and Control M groups. However the
microscopic parameters were different. This may mean
that macroscopic parameters are not reliable indicators of
response to IGFBP-4 gene therapy. This tumour model is
not a survival model. Therefore the long-term outcome of
the gene therapy and effect on animal survival is not
known. As per Home Office guidelines the animals were
sacrificed by Schedule 1 method even before they become
moribund and the tumour attains 2 cm. The expression of
IGFBP-4 was higher in tumours of control P group than
other two groups. It indicates that the IGFBP-4 might have
been used up or prior establishment of tumour could be a
pre requisite for IGFBP-4 expression. Another possible
explanation is tumour cells when deprived of IGF-I for a
long time may be unable to produce IGFBP-4. Both Bcl-2
and Bax expressions were increased in BP-4 group
tumours. IGF-1R expression could not be detected. The
reason for Bcl-2 up regulation after IGFBP-4 gene therapy
is unclear. Perhaps Bcl-2 may have some inverse relation
with IGFBP-4.
(a) Electron microscopic image of tumours of BP-4 group at a magnification of × 710Figure 4
(a) Electron microscopic image of tumours of BP-4 group at a magnification of × 710. Obviously there are numerous apoptotic 
cells with condensed nucleus (arrow) (b)Transmission electron microscopic imaging showing apoptotic cells which are seen as 
apoptotic bodies (arrow) with a shrunken nucleus and a condensed cytoplasm in BP-4 treated tumours (×11500)(c)Transmis-
sion electron microscopic imaging (×11500) showing apoptotic cells with dense masses of chromatin against nuclear membrane 
in BP-4 group tumours (d) Electron microscopy of control P group tumours showing necrotic cells (e) Transmission electron 
microscopic image of control M treated tumours (× 710) showing no apoptotic cells.Page 6 of 8
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vent the establishment of colon cancer from HT-29 cells
in nude mice but it resulted in an increase in apoptosis
indicating IGFBP-4 may influence tumour growth or
development but not cancer initiation. There was an asso-
ciated increase in Bax protein suggesting that it may be the
mechanism of apoptosis.
Conclusion
From our experiment, we conclude that IGFBP-4 gene
therapy in the form localised gene transfer did not prevent
colon cancer initiation and establishment but it increased
in apoptosis and Bax protein expression and a decrease in
tumour cellular mitosis. Further experiments are needed
to find out whether the IGFBP-4 gene therapy can be com-
bined with chemotherapeutic agents in preventing the
establishment of colon cancer in situations such as famil-
ial adenomatous polyposis.
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Western blot (a) and densitometry analysis (b) of Bcl-2 pro-tein in tumours receiving gene construct  with (BP-4) or withou  IGFBP-4 cDNA (co trol C) or no gene constructs (con rol P)Figu e 7
Western blot (a) and densitometry analysis (b) of Bcl-2 pro-
tein in tumours receiving gene constructs with (BP-4) or 
without IGFBP-4 cDNA (control C) or no gene constructs 
(control P). The result showed a higher expression of Bcl-2 
by BP-4 group compared to Control P and M. Values are 
shown as mean ± SEM of 6 animals in each group.
Western blot for IGFBP-4 expression (a) and densitometry analysis (b) f subcutaneous tumours showing higher exp es-sion of IGFBP-4 y Control M than the ther two g oups (P < 0.05)Figure 5
Western blot for IGFBP-4 expression (a) and densitometry 
analysis (b) of subcutaneous tumours showing higher expres-
sion of IGFBP-4 by Control M than the other two groups (P 
< 0.05). Values are expressed as mean ± SEM of 6 animals in 
each group. (Key: control P – tumours without any plasmid treat-
ment, control M – tumours receiving control plasmid therapy, BP-4 
– tumours receiving plasmid with BP-4 construct)
Western blot (a) and densitometry analysis (b) for Bax pro-tein by su cutaneous tumoursFigure 6
Western blot (a) and densitometry analysis (b) for Bax pro-
tein by subcutaneous tumours. BP-4 group tumours showed 
higher expression of Bax protein compared to control 
groups P and M. Values are shown as mean ± SEM. (NS = not 
significant)Page 7 of 8
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